CriticalAntianginal – late sodium current inhibitor×Antituberculous antibiotic
Updated · Methodology
Mechanism
The liver and gut break down most of a ranolazine dose through the enzyme CYP3A4 and a smaller part through CYP2D6. Ranolazine is also a substrate of the transporter P-glycoprotein (ranolazine label, US Food and Drug Administration, FDA). Rifampicin is a potent inducer of drug-metabolising enzymes and transporters, including CYP3A4 and P-glycoprotein, so it can speed up the breakdown of other drugs taken at the same time and weaken their effect (rifampicin summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Rifampicin 600 mg once daily lowers steady-state ranolazine levels by about 95% (ranolazine SmPC, European Medicines Agency, EMA, and ranolazine FDA label). Ranolazine is expected to lose its effect when given with CYP3A4 inducers (ranolazine SmPC, EMA).
Symptoms
Ranolazine is given to adults with stable angina as an add-on when first-line antianginal drugs, such as beta-blockers and calcium antagonists, do not control symptoms or are not tolerated (ranolazine summary of product characteristics, SmPC, European Medicines Agency, EMA). With rifampicin, ranolazine is expected to lose its effect (ranolazine SmPC, EMA), so angina attacks (pressing pain behind the breastbone on exertion) may come back or become more frequent. The fall in ranolazine levels itself causes no symptoms.
Management
The combination is contraindicated: ranolazine must not be taken with CYP3A inducers, and the US label names rifampicin (rifampin) among them (ranolazine label, US Food and Drug Administration, FDA). The European ranolazine summary of product characteristics (SmPC) also says not to use ranolazine in patients taking CYP3A4 inducers, names rifampicin among them and says to avoid starting ranolazine while they are taken (ranolazine SmPC, European Medicines Agency, EMA). Tell the patient that ranolazine must not be taken with rifampicin or other such drugs (ranolazine FDA label). The rifampicin SmPCs do not mention ranolazine. They warn that rifampicin speeds up the breakdown of many drugs and that doses of other drugs may need adjustment when rifampicin is started or stopped (rifampicin SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Interrupting daily rifampicin also carries a risk: renal hypersensitivity reactions have been reported when treatment was resumed after an intended or accidental break (rifampicin SmPC, AEMPS). The documents give no interval between stopping rifampicin and starting ranolazine.
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Ranolazine extended-release tablets (Zydus Lifesciences) – prescribing information (2026)– FDA label, Zydus Lifesciences, DailyMed setid d74f3dea-7357-4e9a-be9a-2f498a44108a, version 5, 09/2026, sections 2.2, 4, 5.1, 7.1 and 7.2
- AEMPS: Ficha técnica de Rifaldin 300 mg cápsulas (rifampicina) (2026)– AEMPS, CIMA, nº registro 46029, secciones 4.3 y 4.5
- EMA: Ficha técnica: Ranolazina, Ranexa (EU/1/08/462), sección 4.4 (2026)– EMA, Ranexa 375 mg comprimidos de liberación prolongada (autorización europea por procedimiento centralizado), ficha técnica en CIMA, nº registro 08462001, consultada 10/2026, sin fecha de revisión en CIMA, secciones 4.1, 4.4 y 4.5